Company intelligence / Profile preview
Catamaran Bio
Cambridge, Massachusetts, United Statescatamaranbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
The company is developing off-the-shelf CAR-NK cell therapies and has advanced two lead CAR-NK cell therapy programs to lead optimization stage as of 2020[3]
- Therapeutic areas
- Oncology
- Modalities
- CAR-NK cell therapiesallogeneic cell therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
OmniaBio Inc. (for development and manufacturing of allogeneic CAR-NK cell therapies)[4]
Beyond the preview
Go deeper on Catamaran Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catamaran Bio.